Impact of Skeletal Muscle Quality and Loss on the Outcome of Liver Transplantation

NCT ID: NCT06188273

Last Updated: 2024-01-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

800 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2029-01-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

CT imaging-based skeletal muscle assessment has been found to predict the outcomes of many diseases. Previous evidence revealed that pre-transplant muscle quality and post-transplant muscle loss were associated with transplant outcomes. However, there is no prospective study supporting the aforementioned conclusions. This study aims to prospectively include liver transplant patients from multiple transplant centers, collecting their pre-transplant CT images as well as post-transplant CT images at specific time points. The objective is to further explore and clarify the correlation between skeletal muscle assessment and the prognosis of liver transplant patients. The goal is to provide guidance for peri-transplant health monitoring and disease intervention for liver transplant patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Transplantation Muscle Loss Muscle Quality

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Myosteatotic Group

The group of patients was diagnosed with myosteatosis through CT imaging assessment before transplantation.

No interventions assigned to this group

Non-myosteatotic Group

The group of patients was diagnosed without myosteatosis through CT imaging assessment before transplantation.

No interventions assigned to this group

The Group with Severe Muscle Loss

The group of patients, through the comparison of CT images before and after transplantation, was diagnosed with significant muscle loss.

No interventions assigned to this group

The Group without Severe Muscle Loss

The group of patients, through the comparison of CT images before and after transplantation, was diagnosed without significant muscle loss.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patients undergoing deceased donor liver transplantation (DDLT) for the first time

Exclusion Criteria

* Pediatric transplants
* Presence of portal vein tumor thrombus according to imageing before transplantation
* Presence of macrovascular invasion according to imageing before transplantation
* Re-transplants
* Multi-organ transplants
* Patients who died within 30 days after transplantation
* Patients diagnosed with skeletal muscle diseases (e.g. muscle atrophy)
* Patients with serious medical conditions such as heart failure, persistent infection, and renal insufficiency.
Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

First Affiliated Hospital of Zhejiang University

OTHER

Sponsor Role collaborator

Shulan (Hangzhou) Hospital

OTHER

Sponsor Role collaborator

The Affiliated Hospital of Qingdao University

OTHER

Sponsor Role collaborator

West China Hospital

OTHER

Sponsor Role collaborator

Huashan Hospital

OTHER

Sponsor Role collaborator

Zhejiang University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Xiao Xu

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CT2023-ZJU-OBS3

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.